Author Archives for: Jesse Spacco

Protein Expression May Predict Response to Radiation Therapy for Head and Neck Patients

Platinum chemotherapy using agents such as cisplatin is an important treatment for squamous cell carcinoma of the head and neck (SCCHN), while chemoradiation is often used for SCCHN patients with high-risk clinical features. Considering the significant morbidity of these treatments, it is important that they are administered only to those patients who are likely to benefit. The excision repair cross-complementing group 1 (ERCC1) enzyme has an essential role in the pathways used by cancer cells to control damage from cisplatin-based chemotherapy and chemoradiation, and therefore ERCC1+ tumors are more resistant to cisplatin and radiation than ERCC1− cell lines. These roles … Continue Reading »

Comments Off

Q&A: Henry C. Fung, MD

Henry C. Fung, MD, a nationally recognized leader in hematologic oncology, has joined the Fox Chase faculty to oversee an expansion of the hematologic malignancy program. Fung, who came to Fox Chase from Rush University Medical Center in Chicago, serves as clinical leader of the blood cancers program and the hematologic oncology service line and a professor of medical oncology, as well as director of the Temple University Hospital Bone Marrow Transplant Program. Continue Reading »

Comments Off